Book a Meeting

Anti-IGHE Antibody, Non-Fucosylated (BioBet-279ZP) (CAT#: BioBet-279ZP) Datasheet

Target
IGHE
Isotype
IgG1, κ
Description
Anti-IGHE Antibody, Non-Fucosylated (BioBet-279ZP) is a humanized monoclonal IgG1, κ antibody against IGHE. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Asthma
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced IGHE antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
IGHE
Full Name
Immunoglobulin Heavy Constant Epsilon
Background
IGHE (Immunoglobulin Heavy Constant Epsilon) is a Protein Coding gene.
Diseases associated with IGHE include Toxocariasis and Allergic Rhinitis.
Among its related pathways are Cytokine Signaling in Immune system and Innate Immune System.
Gene Ontology (GO) annotations related to this gene include antigen binding.
An important paralog of this gene is IGHG2.
Alternative Names
Quilizumab; 1228538-47-3; RG7449; MEMP1972A; 47H4; IGHE; Immunoglobulin heavy constant epsilon;
Gene ID
Cellular Localization
Plasma membrane, Extracellular region or secreted
Involvement in Disease
Diseases associated with IGHE include Toxocariasis and Latex Allergy.
Related Pathways
Its related pathways are RET signaling and GAB1 signalosome.
Function
Immunoglobulin heavy chain immobilization region. Immunoglobulins, also called antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition stage of humoral immunity, membrane-bound immunoglobulin acts as a receptor and binds to a specific antigen to trigger the expansion of B lymphocyte clones and differentiate into plasma cells that secrete immunoglobulin. The secreted immunoglobulin mediates the fluid immune response phase, leading to the elimination of bound antigens. The antigen binding site is composed of a variable domain of a heavy chain and a variable domain of a light chain related to it. Therefore, each immunoglobulin has two antigen binding sites that have significant affinity for a specific antigen. The variable domains are assembled through a process called V-(D)-j rearrangement, followed by somatic hypermutation, which allows the affinity maturation of specific antigens after exposure to antigen and selection 发送反馈 历史记录
Post-translational modifications
1.Glycosylation at Asn21, Asn49, Asn99, Asn146, Asn252, and Asn275 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, κ
Antibody Clone
BioBet-279ZP
Host
Humanized
Species Reactivity
Human
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IGHE.
Antibody Indication
Asthma

Asthma

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.